Cocrystal Pharma (COCP) AI Stock Analysis

• Market Cap: $15.71M
• Dividend Yield: N/A
• Average Volume (3M): 3.12M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.46
• Revenue Growth: N/A
• EPS Growth: 49.10%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 13,784,065
• 10 Day Avg. Volume: 178,720
• 30 Day Avg. Volume: 3,115,767
• PEG Ratio: >-0.01
• Price to Book (P/B): 2.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.25
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -8.42
• Enterprise Value/Ebitda: -1.24
• 1Y Price Target: $10.00
• Price Target Upside: 800.90% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $0.96 ▼(-13.96% Downside)

The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn, shrinking equity base). Technicals also remain bearish with the stock below major moving averages, while positive corporate milestones (trial initiation steps, NIH funding, and insider financing) provide partial offset but do not fully mitigate the fundamental funding and execution risks.

Positive Factors

Advancement of Norovirus Antiviral

The advancement of CDI-988 positions Cocrystal Pharma as a significant player in the antiviral market, potentially offering a first-in-class oral solution for norovirus, addressing unmet medical needs and enhancing its competitive edge.

Equity Incentive Plan

The 2025 Equity Incentive Plan aligns key personnel's interests with company growth, potentially enhancing talent retention and motivation, which is crucial for long-term strategic execution and market competitiveness.

Proprietary Drug Discovery Technology

Cocrystal Pharma's proprietary technology provides a competitive advantage in developing novel antiviral therapeutics, potentially leading to successful partnerships and revenue opportunities through unique solutions.

Negative Factors

Zero Revenue

The lack of revenue generation indicates challenges in monetizing its drug pipeline, which could hinder financial sustainability and limit investment in R&D, affecting long-term growth prospects.

Ongoing Operational Losses

Persistent operational losses reflect difficulties in achieving profitability, which may strain resources and necessitate additional funding, impacting financial stability and strategic flexibility.

Declining Total Assets and Equity

A decline in assets and equity suggests weakening financial health, potentially limiting the company's ability to invest in growth initiatives and respond to market opportunities effectively.

Cocrystal Pharma Business Overview & Revenue Model

Company Description

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

How the Company Makes Money

Cocrystal Pharma generates revenue primarily through collaborative agreements, licensing deals, and research and development contracts with other pharmaceutical companies. These partnerships often include upfront payments, milestone payments, and royalties based on the successful development and commercialization of targeted antiviral therapies. The company's revenue streams are significantly influenced by its ability to advance its drug candidates through clinical trials and secure strategic partnerships that leverage its proprietary drug discovery technology. Additionally, government grants or funding related to its research areas may also contribute to its financials, although this is less consistent compared to contractual collaborations.

Cocrystal Pharma Financial Statement Overview

Summary

Cocrystal Pharma's financial performance is severely impacted by the lack of revenue and ongoing operational losses, as indicated by the low score of 15 for the income statement. While the balance sheet suggests low leverage with a score of 40, the decline in total assets and equity is concerning. Cash flow issues are evident with a score of 25, reflecting negative operating cash flows and liquidity challenges.

Income Statement

Cocrystal Pharma has reported zero revenue for the past three years, indicating a lack of income generation. The company has consistently reported negative EBIT, EBITDA, and net income, reflecting ongoing operational losses and challenges in achieving profitability. The absence of revenue underscores a challenging growth trajectory in the highly competitive biotechnology sector.

Balance Sheet

The company maintains a strong equity position with a low debt-to-equity ratio, suggesting low leverage and a potentially stable financial structure. However, the consistent decline in total assets and stockholders' equity over the years signals potential financial deterioration. The equity ratio remains robust, indicating that a significant portion of the company's assets is financed by equity rather than debt.

Cash Flow

Cocrystal Pharma has experienced declining operating cash flows, reflecting ongoing struggles in cash generation from operations. Despite this, the company manages to maintain a positive free cash flow to net income ratio, suggesting efficient cash flow management relative to its net losses. However, the lack of free cash flow growth and consistent negative operating cash flow highlight ongoing liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	2.01M
Gross Profit	-1.42M	-12.54M	-15.17M	-12.39M	-8.79M	-4.02M
EBITDA	-9.68M	-17.75M	-20.97M	-17.95M	-14.03M	-9.43M
Net Income	-9.67M	-17.50M	-17.98M	-38.84M	-14.19M	-9.65M
Balance Sheet
Total Assets	10.45M	13.46M	31.26M	40.84M	79.39M	54.24M
Cash, Cash Equivalents and Short-Term Investments	7.73M	9.86M	26.35M	37.14M	58.70M	33.01M
Total Debt	1.58M	1.81M	1.85M	297.00K	534.00K	596.00K
Total Liabilities	2.78M	3.93M	4.88M	1.27M	1.84M	1.74M
Stockholders Equity	7.67M	9.52M	26.38M	39.57M	77.55M	52.51M
Cash Flow
Free Cash Flow	-9.82M	-16.49M	-14.78M	-21.51M	-12.77M	-10.07M
Operating Cash Flow	-9.80M	-16.48M	-14.67M	-21.43M	-12.72M	-9.83M
Investing Cash Flow	-12.56K	-8.00K	-118.00K	-74.00K	-52.00K	-240.00K
Financing Cash Flow	4.54M	0.00	3.99M	-27.00K	38.47M	35.66M

Cocrystal Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.11
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COCP, the sentiment is Positive. The current price of 1.11 is above the 20-day moving average (MA) of 1.02, above the 50-day MA of 1.03, and below the 200-day MA of 1.35, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 60.97 is Neutral, neither overbought nor oversold. The STOCH value of 76.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COCP.

Cocrystal Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNSE	46 Neutral	$14.65M	-0.54	-67.47%	―	―	9.63%
COCP	45 Neutral	$15.71M	-1.19	-94.94%	―	―	49.10%
CLRB	44 Neutral	$13.06M	-0.36	-145.42%	―	―	79.31%
BRTX	44 Neutral	$10.61M	-0.78	-207.73%	―	1.70%	-111.67%
IMRN	38 Underperform	$7.89M	-1.67	-49.00%	―	47.17%	26.84%
BIVI	38 Underperform	$9.58M	-0.14	-94.79%	―	―	84.44%

Cocrystal Pharma Corporate Events

Cocrystal Pharma gains IRB approval for norovirus trial

On December 18, 2025, Cocrystal Pharma announced that the Institutional Review Board at Emory University School of Medicine approved the initiation of a Phase 1b human challenge study of its oral antiviral candidate CDI-988 for the prevention and treatment of norovirus infections, with subject screening already underway and enrollment planned to begin in the first quarter of 2026. CDI-988, designed as a broad-spectrum inhibitor targeting a conserved region of the norovirus 3CL protease and previously shown in August 2025 to have favorable Phase 1 safety and tolerability data, will be tested in a randomized, double-blind, placebo-controlled trial of up to 40 healthy adults to assess efficacy in reducing clinical symptoms, viral shedding and disease severity, as well as safety and pharmacokinetics; the program underscores Cocrystal’s bid to address a major unmet medical need in norovirus, where no approved treatments or vaccines exist despite substantial global health and economic burdens.

The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.

Cocrystal Pharma to Present at Emerging Growth Conference

On December 1, 2025, Cocrystal Pharma announced that its CFO and Co-CEO, James Martin, will present a company overview and clinical progress update at the Noble Capital Markets 21st Emerging Growth Equity Conference on December 3, 2025. This presentation could enhance the company’s visibility and provide stakeholders with insights into its strategic direction and progress in antiviral drug development.

The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.

Cocrystal Pharma Completes $1.03M Private Placement

On October 30, 2025, Cocrystal Pharma announced the completion of a private placement of units priced at-the-market under Nasdaq rules, raising $1.03 million through the sale of 743,024 shares of common stock and unregistered warrants for additional potential proceeds of $1.83 million. The investment, made by company insiders including directors and management, demonstrates confidence in Cocrystal’s mission to advance antiviral therapies and strengthens its financial position as it approaches key clinical milestones.

The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.

Cocrystal Pharma Secures NIH Award for Antiviral Research

On October 27, 2025, Cocrystal Pharma announced it received a Small Business Innovation Research Phase I award from the NIH and NIAID to support the development of a novel oral antiviral candidate for influenza A and B. This $500,000 award will help advance their influenza inhibitor program, potentially leading to further funding opportunities and strengthening their position in antiviral drug development.

The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.